{"classes":[{"categories":[{"measurements":[{"comment":"No patients were analyzed for this arm.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"100.0"},{"comment":"No patients were analyzed for this arm.","groupId":"OG002","value":"NA"},{"comment":"No patients were analyzed for this arm.","groupId":"OG003","value":"NA"},{"comment":"No patients were analyzed for this arm.","groupId":"OG004","value":"NA"}]}],"title":"Day 1 (total=0, 1, 0, 0, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"75.0"},{"groupId":"OG002","value":"87.5"},{"groupId":"OG003","value":"82.4"},{"groupId":"OG004","value":"37.5"}]}],"title":"Day 5 (total = 6, 4, 8, 17, 8)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"75.0"},{"groupId":"OG003","value":"82.4"},{"groupId":"OG004","value":"57.1"}]}],"title":"Day 8 (total = 5, 4, 8, 17, 7)"},{"categories":[{"measurements":[{"comment":"No patients were analyzed for this arm.","groupId":"OG000","value":"NA"},{"comment":"No patients were analyzed for this arm.","groupId":"OG001","value":"NA"},{"comment":"No patients were analyzed for this arm.","groupId":"OG002","value":"NA"},{"comment":"No patients were analyzed for this arm.","groupId":"OG003","value":"NA"},{"groupId":"OG004","value":"100.0"}]}],"title":"Day 10 (total=0, 0, 0, 0, 0, 1)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7"},{"groupId":"OG001","value":"33.3"},{"groupId":"OG002","value":"50.0"},{"groupId":"OG003","value":"50.0"},{"groupId":"OG004","value":"50.0"}]}],"title":"Day 15 (total=3, 3, 4, 2, 2)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"49"},{"groupId":"OG004","value":"11"}],"units":"Participants"}],"description":"Reporting the number of patients with a reading at the timepoint in the dose group.","groups":[{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.","id":"OG000","title":"Arm 1, Group X (20 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.","id":"OG001","title":"Arm 1, Group X (30 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.","id":"OG002","title":"Arm 1, Group X (40 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.","id":"OG003","title":"Arm 1, Group X (60 mg)"},{"description":"Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), as part of a 28-day treatment cycle. Group X is a sub-arm, based on disease indication.","id":"OG004","title":"Arm 1, Group X (80 mg)"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set N=number of participants analyzed. total n=number of patients with a reading at the timepoint in the dose group.","reportingStatus":"POSTED","timeFrame":"Days 1, 5, 8, 10, 15","title":"Percentages of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 1 (MWF Every Week), Group X","type":"SECONDARY","unitOfMeasure":"Percentages of participants"}